This is a working overview of Thymosin alpha 1, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-05-20 and is reviewed periodically as new material appears.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | About 3.1 kDa | 28 residues, N-terminally acetylated |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Freely soluble in water | Also soluble in aqueous buffers |
| Storage temperature | 2 to 8 °C | Protect from light and moisture |
| Common synonyms | Thymalfasin; Tα1 | Same peptide sequence |
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.
Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.
Stability depends on temperature, pH, and the number of freeze-thaw events the sample has experienced. Freeze-dried material is commonly held at -20 °C or colder, while reconstituted liquid is kept cold and used within a short window. Extreme pH and prolonged light exposure can promote deamidation, oxidation, or aggregation, particularly at asparagine and methionine positions. Adsorption to container walls can lower the measured concentration of a dilute solution even when the peptide molecules themselves remain intact.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
== History == Healing the Wounds was founded by Kevin Richards in 2009. Richards had previously served with the Royal Regiment of Wales as a combat medic and completed tours of duty in numerous countries including Northern Ireland and Operation Desert Storm. His involvement with the Royal Welsh Veterans Association and his own background in army medicine led him to recognise the lack of support for PTSD sufferers in Wales and made him determined to do something to help.
Examination of remains of Homo erectus from Kenya, which are about 1.6 million years old, has revealed signs typical of yaws. The genetic analysis of the yaws causative bacteria—Treponema pallidum pertenue—has led to the conclusion that yaws is the most ancient of the four known Treponema diseases. All other Treponema pallidum subspecies probably evolved from Treponema pallidum pertenue. Yaws is believed to have originated in tropical areas of Africa and spread to other tropical areas of the world via immigration and the slave trade. The latter is likely the way it was introduced to Europe from Africa in the 15th century. The first unambiguous description of yaws was made by the Dutch physician Willem Piso. Yaws was clearly described in 1679 among African slaves by Thomas Sydenham in his epistle on venereal diseases, although he thought that it was the same disease as syphilis. The causative agent of yaws was discovered in 1905 by Aldo Castellani in ulcers of patients from Ceylon. The current English name is believed to be of Carib origin, from "yaya", meaning sore. Towards the end of the Second World War, yaws became widespread in the North of Malaya under Japanese occupation. After the country was liberated, the population was treated for yaws by injections of salvarsan, of which there was a great shortage, so only those with stage 1 were treated.
Liquid water is present on Earth, covering 71% of its surface. Liquid water is also occasionally present in small amounts on Mars. Scientists believe liquid water is present in the Saturnian moons of Enceladus, as a 10-kilometre thick ocean approximately 30–40 kilometers below Enceladus' south polar surface, and Titan, as a subsurface layer, possibly mixed with ammonia. Jupiter's moon Europa has surface characteristics which suggest a subsurface liquid water ocean. Liquid water may also exist on Jupiter's moon Ganymede as a layer sandwiched between high pressure ice and rock.
== NAD+ precursors == The members of the NAD+ precursor family include tryptophan (Trp), nicotinic acid (NA), nicotinamide (NAM), nicotinamide ribose (NR), nicotinamide mononucleotide (NMN), reduced nicotinamide ribose (NRH) and reduced nicotinamide mononucleotide (NMNH) of these, the majority are logically vitamin B substances or their congeners Based on the bioavailability of its precursors, there are three pathways for the synthesis of NAD+ in cells.
Sources: en.wikipedia.org
The chemical ecology of plant-insect interaction is a significant subfield of chemical ecology. In particular, plants and insects are often involved in a chemical evolutionary arms race. As plants develop chemical defenses to herbivory, insects which feed on them co-evolved to develop immunity to these poisons, and in some cases, repurpose these poisons for their own chemical defense against predators. For example, caterpillars of the monarch butterfly sequester cardenolide toxins from their milkweed host-plants and are able to use them as an anti-predator defense. Whereas most insects are killed by cardenolides, which are potent inhibitors of the Na+/K+-ATPase, monarchs have evolved resistance to the toxin over their long evolutionary history with milkweeds. Other examples of sequestration include the tobacco hornworm Manduca sexta, which use nicotine sequestered from tobacco plants in predator defense; and the bella moth, which secretes a quinone-containing froth to deter predators obtained from feeding on Crotalaria plants as a caterpillar. Chemical ecologists also study chemical interactions involved in indirect defenses of plants, such as the attraction of predators and parasitoids through herbivore-induced volatile organic compounds (VOCs).
The chain-termination method developed by Frederick Sanger and coworkers in 1977 soon became the method of choice, owing to its relative ease and reliability. When invented, the chain-terminator method used fewer toxic chemicals and lower amounts of radioactivity than the Maxam and Gilbert method. Because of its comparative ease, the Sanger method was soon automated and was the method used in the first generation of DNA sequencers. Sanger sequencing is the method which prevailed from the 1980s until the mid-2000s. Over that period, great advances were made in the technique, such as fluorescent labelling, capillary electrophoresis, and general automation. These developments allowed much more efficient sequencing, leading to lower costs. The Sanger method, in mass production form, is the technology which produced the first human genome in 2001, ushering in the age of genomics. However, later in the decade, radically different approaches reached the market, bringing the cost per genome down from $100 million in 2001 to $10,000 in 2011.
The chemical elements humans consume in the largest quantities are carbon, hydrogen, nitrogen, oxygen, phosphorus, and sulphur, summarized as CHNOPS. The chemical compounds that humans consume in the largest quantities and provide bulk energy are classified as carbohydrates, proteins, and fats. Water must be also consumed in large quantities but does not provide caloric value. Calcium, sodium, potassium, magnesium, and chloride ions, along with phosphorus and sulfur, are listed with macronutrients because they are required in large quantities compared to micronutrients, i.e., vitamins and other minerals, the latter often described as trace or ultratrace minerals. Macronutrients provide energy:
==== Inner city development ==== Heseltine faced initial suspicion from Labour-led Merseyside Council, but got on well with Sir Trevor Jones, Liberal leader of Liverpool City Council. Jones, also a self-made businessman, got on well with Heseltine, and Jones claimed that Heseltine admitted to him late one night that he was a Liberal at heart, but could not bear the thought of having no realistic chance to win power. Inspired by the Bundesgartenschauen which had helped to regenerate German cities after the war, Heseltine arranged for the first of five biennial National garden festivals to be held in Liverpool in 1984 (Jones arranged for the council to delegate the bid to the Merseyside Development Corporation, of which he was a director). More than 3 million people eventually attended. Heseltine arranged for Liverpool to receive unused government grants for other cities (from the Urban Programme), although the money was less than had been clawed back from Liverpool through council spending cuts. He also played an important role in the redevelopment of Albert Dock, the development of Wavertree Technology Park (the land purchased by £10 million of public money) and the development of Cantril Farm estate into Stockbridge Village, arranging for Barratt Developments to build many new houses for owner occupiers. Heseltine also played an important role in the development of Urban Development Corporations, directly appointed by the minister and overriding local authority planning controls to spend government money on infrastructure.
== Further reading == Singerman, Ariel; Useche, Pilar (26 February 2019). "FE983/FE983: Impact of Citrus Greening on Citrus Operations in Florida". University of Florida Institute of Food and Agricultural Sciences Electronic Data Information Source. Retrieved 16 February 2021. Zheng, Desen; Armstrong, Cheryl M; Yao, Wei; Wu, Bo; Luo, Weiqi; Powell, Charles; Hunter, Wayne; Luo, Feng; Gabriel, Dean; Duan, Yongping (10 January 2024). "Towards the completion of Koch's postulates for the citrus huanglongbing bacterium, Candidatus Liberibacter asiaticus". Horticulture Research. 11 (3). Oxford University Press. doi:10.1093/hr/uhae011. PMC 11783299. Hunter, W.B., Sinisterra-Hunter, X. 2018. Emerging RNA Suppression Technologies to Protect Citrus Trees from Citrus Greening Disease Bacteria. Advances in Insect Physiology 55:163-199. https://doi.org/10.1016/bs.aiip.2018.08.001 Sandoval-Mojica, A.F.; Altman, S.; Hunter, W.B.; Pelz-Stelinski, K.S. 2020. Peptide conjugated morpholino's for management of the Huanglongbing pathosystem. Pest Manag. Sci. doi: 10.1002/ps.5877. https://doi:101002/ps.5877 Sandoval-Mojica, A.G.; Hunter, W.B.; Aishwarya, V.; Bonilla, S.; Pelz-Stelinski, K.S. Antibacterial FANA oligonucleotides as a novel approach for managing the Huanglongbing pathosystem. Sci. Rep. 11:2760. (2021). doi:10.1038/s41598-021-82425-8 Hunter, W.B.; Cooper, W.R.; Sandoval-Mojica, A.F.; McCollum, G.; Aishwarya, V.; Pelz-Stelinski, K.S. (2021).
Sources: en.wikipedia.org
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.
The name traces back to thymosin fraction 5, a crude thymus extract examined in the 1970s. Individual peptides in that mixture were labeled with Greek letters, and alpha-1 was one of them. The international nonproprietary name thymalfasin was assigned later.
No. Thymosin beta-4 contains 43 residues and binds actin, while thymosin alpha-1 contains 28 residues and acts on immune cells. The two sit in a historical naming group but share no sequence similarity, and they are not substitutes for one another.
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.